



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 11, 2015

Via E-mail

Zeev Weiss  
Chief Executive Officer  
Intec Pharma Ltd.  
12 Hartom Street  
Har Hotzvim, Jerusalem 777512, Israel

**Re: Intec Pharma Ltd.  
Amendment No. 1 to Draft Registration Statement on Form F-1  
Submitted June 1, 2015  
CIK No. 0001638381**

Dear Mr. Weiss:

We have reviewed your amended draft registration statement and have the following comment.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Business

New Product Development for Global Pharmaceutical Company, page 67

1. We note that you have entered into a new product development agreement with a global pharmaceutical company. Please revise your disclosure where you discuss the product development agreement to identify the counterparty to the agreement, the duration of the agreement, the duration of the applicable royalty payment obligation and any material early termination provisions.

Zeev Weiss  
Intec Pharma Ltd.  
June 11, 2015  
Page 2

You may contact Tabatha McCullom at (202) 551-3658 or Lisa Vanjoske at (202) 551-3614 if you have questions regarding comments on the financial statements and related matters. Please contact Matthew Jones at (202) 551-3786, Bryan Pitko at (202) 551-3203 or me at (202) 551-3715 with any other questions.

Sincerely,

*/s/ Bryan J. Pitko* for

Jeffrey P. Riedler  
Assistant Director

cc: Robert L. Grossman, Esq.  
Joshua M. Samek, Esq.  
Greenberg Traurig, P.A.  
333 Avenue of the Americas  
Miami, FL 33131